Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • The Inquiry Report
    • Additional Compensation Report
    • First Interim Report
    • Second Interim Report
    • Compensation Framework Study
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • NHS Psychological Support
    • Confidential Psychological Support
    • Support Groups
    • Infected Blood Support Schemes
    • Treatment and aftercare
    • Medical Evidence
    • Expenses Guidance
  • Contact us
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

Subscribe to Search results

The Belfast Haemophilia annual returns for 1978 showed the use of cryoprecipitate (250,646), NHS concentrate (186,992), Hemofil (290,599) and Kryobulin (334,390).

Published on: 27 September, 2024

In 1979 the vast bulk of treatment at the Belfast Haemophilia Centre was with commercial concentrates (Hemofil: 557,655 units, Kryobulin: 440,051).

Published on: 27 September, 2024

In her statement to the Inquiry, Dr Mayne noted that she performed liver function tests on patients at Belfast Haemophilia Centre as she was apprehensive about the long term effects of IV treatment.

Published on: 27 September, 2024

In a HIV Haemophilia litigation report, Dr Mayne suggested that the risk of NANB could progress to Hepatitis was known in 1977 but the full significance of its effects was not investigated until the mid-late 1980's.

Published on: 27 September, 2024

Eric Preston in his statement to the Lindsay Tribunal noted that the haemophilia centre at Sheffield was first based at the Royal Infirmary before moving to Royal Hallamshire Hospital. It was a reference centre but not one of the larger reference centres.

Published on: 27 September, 2024

The first director of the Haemophilia Centre at Sheffield was Professor Eddie Blackburn.

Published on: 27 September, 2024

In his statement to the Lindsay Tribunal, Dr Preston believed that in 1978 it had been shown that Non A-Non B Hepatitis was a very serious disorder.

Published on: 27 September, 2024

In his statement to the Lindsay Tribunal, Dr Preston asserted that the amount of Factor VIII and Factor IX given in the Haemophilia Centre was much less than that in other centres.

Published on: 27 September, 2024

Sheffield Haemophilia Centre participated in a formal trial of an Armour heat-treated concentrate beginning in April 1984. Two patients became ill with hepatitis. Dr Preston's recollection was that they withdrew from that study and moved to a study with colleagues in other centres, using an Alpha product.

Published on: 27 September, 2024

The Sheffield haemophilia centre was a reference centre, but not one of the larger centres. At Sheffield, there was a particular focus on hepatitis and liver disease, with significant research being undertaken there.

Published on: 27 September, 2024

At the Sheffield haemophilia centre, the amount of Factor 8 and Factor 9 given to patients was very much less than other reference centres, although Dr Preston did not think this reflected a deliberate decision to take a conservative approach.

Published on: 27 September, 2024

Dr Preston told the Observer "in 1978 we showed quite definitely that non-A, non-B was a very serious disorder. The Department of Health should have responded by pushing for ways to inactivate the virus in the blood, or given patients the choice of an alternative."

Published on: 27 September, 2024

Dr Preston confirmed his views to the Inquiry that "The Department of Health should have responded by pushing for ways to inactivate the virus in the blood, or given patients the choice of an alternative."

Published on: 27 September, 2024

A survey between Sheffield and the Royal Free showed that approximately one third of the patients studied had the appearance of chronic active (aggressive) hepatitis.

Published on: 27 September, 2024

Dr Preston's policy was to treat people with mild haemophilia with DDAVP as soon as it became available.

Published on: 27 September, 2024

Dr Preston stated in his evidence to the Inquiry that whilst the hepatitis risk from commercial products was substantially greater than from NHS products, "there were insufficient NHS products for the treatment of Royal Hallamshire Hospital patients".

Published on: 27 September, 2024

Dr Preston confirmed that part of his approach to patients was to "keep individual patients on the same concentrate, and the same 'batch' for as long as possible to minimise exposure to different blood donations"

Published on: 27 September, 2024

Dr Preston does not recall telling patients that the treatment they were receiving might expose them to the risk of chronic liver disease.

Published on: 27 September, 2024

Dr preston's view was that the amount of Factor 8 (and Factor 9) given to patients was very much less than the majority of other reference centres.

Published on: 27 September, 2024

Dr Preston's approach to purchasing a number of different commercial concentrates was "not putting all the eggs in one basket in case something happened with the supply chain..." and "keep individual patients on the same concentrate, and the same 'batch' for as long as possible to minimise exposure to different blood donations."

Published on: 27 September, 2024

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 2322
  • Page 2323
  • Page 2324
  • Page 2325
  • Current page 2326
  • Page 2327
  • Page 2328
  • Page 2329
  • Page 2330
  • …
  • Next page Next
  • Last page Last

Inquiry

  • Home
  • About
  • Approach
  • Participate
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.